Johnson & Johnson Joins Forces With Veracyte For Lung Cancer Diagnostics
Executive Summary
Johnson & Johnson has entered a strategic collaboration with genomics diagnostics company Veracyte to develop and commercialize tests for detecting lung cancer.
You may also be interested in...
Veracyte, J&J Launch NOBLE Trial For Lung Cancer Detection
The 9,000-patient clinical study will identify genomic and other differences in lung cancer development and progression among patients with lung nodules detected by computed tomography.
Life After NASH For CymaBay: An Interview With CEO Sujal Shah
With up to $100m from Abingworth and a recent $75m FOPO, CymaBay has runway to await pivotal data in primary biliary cholangitis in 2023 for seladelpar, after the candidate failed in NASH. It sees a significant market opportunity in the second-line setting cornered by Intercept.
FDA, Industry To Miss MDUFA V Congressional Deadline; Insiders At Odds Over Future Of Deal
The US agency and the medtech industry still have significant disagreements, which means they will miss a 15 January deadline to send the MDUFA V user-fee deal to Congress. Insiders disagree, however, on how severe those disagreements are and when a deal can be reached.